CSL Behring GmbH
8 products tracked · names used in filings: CSL Behring GmbH
Upcoming milestones
No upcoming milestones listed.
Recent milestones
No recent milestones.
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Andembry garadacimab | Authorised | 2025-02-10 |
| 🇪🇺 | Hemgenix etranacogene dezaparvovec | Authorised | 2023-02-20 |
| 🇪🇺 | Afstyla lonoctocog alfa | Authorised | 2017-01-04 |
| 🇪🇺 | Idelvion albutrepenonacog alfa | Authorised | 2016-05-11 |
| 🇪🇺 | Respreeza alpha1-proteinase inhibitor (human) | Authorised | 2015-08-20 |
| 🇪🇺 | Voncento human coagulation factor VIII / human von willebrand factor | Authorised | 2013-08-12 |
| 🇪🇺 | Hizentra human normal immunoglobulin (SCIg) | Authorised | 2011-04-14 |
| 🇪🇺 | Privigen human normal immunoglobulin (IVIg) | Authorised | 2008-04-24 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.